Point Bio­phar­ma’s close­ly watched prostate can­cer ra­dio­phar­ma­ceu­ti­cal study dis­ap­points, Lil­ly again ex­tends of­fer

Point Bio­phar­ma’s ra­dio­phar­ma­ceu­ti­cal prostate can­cer treat­ment staved off dis­ease pro­gres­sion or death by 3.5 months com­pared to hor­mone ther­a­py in a close­ly watched Phase III tri­al.

How­ev­er, an­a­lysts said the re­sults dis­ap­point­ed com­pared to a sim­i­lar ther­a­py from No­var­tis. The da­ta come at a piv­otal time for the com­pa­ny, with share­hold­ers hold­ing out against an ac­qui­si­tion of­fer from Eli Lil­ly in hopes of a bet­ter deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER